Corpus overview


Overview

MeSH Disease

Human Phenotype

Cough (9)

Fatigue (8)

Headache (8)

Fever (8)

Myalgia (5)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 13
    records per page




    Reversible Lesion of the Corpus Callosum MESHD Associated With COVID-19: A Case Report and Review of Literature MESHD

    Authors: Yagmur Inalkac Gemici; Irem Tasci

    doi:10.21203/rs.3.rs-81684/v1 Date: 2020-09-21 Source: ResearchSquare

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may affect the central nervous system (CNS) and peripheral nervous system (PNS). Major CNS manifestations of SARS-CoV-2 include seizures HP seizures MESHD, meningitis HP meningitis MESHD, meningoencephalitis MESHD, ischemic stroke HP ischemic stroke MESHD, hemorrhagic stroke MESHD stroke HP, anosmia HP anosmia MESHD, hypogeusia MESHD, acute disseminated encephalomyelitis MESHD, hemorrhagic necrotizing encephalopathy MESHD necrotizing encephalopathy HP, and nonfocal phenomena including lethargy HP, agitation HP agitation MESHD, confusion HP confusion MESHD, headache HP headache MESHD, and ataxia HP ataxia MESHD. The reversible splenial lesion syndrome MESHD ( MERS MESHD) was first described in 2004. Although MERS was initially recognized as a benign phenomenon, a second type of MERS was identified in later years, which has a poor prognosis and potentially serious sequela. MERS can be caused by numerous etiologies including viruses. In this report, we present a patient with SARS-CoV-2 who presented with ataxia HP ataxia MESHD and dizziness MESHD as the clinical symptoms of MERS, which is a rare clinical phenomenon and can be caused by numerous etiologies.

    A case report of moderate COVID-19 with an extremely long-term viral shedding period in China

    Authors: yonghong wang; chaoyuan liu; qinghui meng; shuang gui; yu wu; pengjiang cheng; peng wang; xiuyong liao

    doi:10.21203/rs.3.rs-59700/v1 Date: 2020-08-14 Source: ResearchSquare

    BackgroundAn ongoing outbreak of novel coronavirus disease MESHD 2019 (COVID-19) from Wuhan, China, is currently recognized as a global public health emergency, which has subsequently spread to the rest of China and other countries. The WHO raised the COVID-19 alert to the highest level. The virus is a new highly contagious via human-to-human transmission TRANS. The median duration of viral shedding is 20.0 days. We report that the longest duration of viral shedding was 32.0 days from illness onset in a patient with moderate COVID-19 admitted to QianJiang Central Hospital.Case presentationA 37-year-old male TRANS sought medical advice while suffering from fever HP fever MESHD, dry cough MESHD cough HP, fatigue HP fatigue MESHD, dizziness MESHD, runny nose and diarrhoea MESHD. Five days before the visit, he had a history of travel TRANS from affected geographic areas. The patient had a positive RT-PCR test, and chest CT images showed multiple nodules and mixed ground-glass opacification with consolidation in both lungs. Laboratory findings showed that his lymphocyte and CD4+ counts were below the normal range. The patient was given antiviral treatment, including arbidol, lopinavir, IFN-α, and traditional Chinese medicine, and other necessary support care. All clinical symptoms and CT imaging manifestation abnormalities resolved during the course of therapy.ConclusionAlthough the positive RT-PCR tests were verified in consecutive upper respiratory specimens, the clinical symptoms, CT imaging findings, CD4 + lymphocyte counts, and IgG antibody SERO levels had obviously improved. Positive tests may be detecting pieces of inactive viruses, which would not be transmissible in individual cases.

    Neurological Manifestations and Complications of Coronavirus Disease MESHD 2019 (COVID-19): A Systematic Review and Meta-Analysis 

    Authors: Ahmed Yassin; Mohammed Nawaiseh; Ala' Shaban; Khalid Alsherbini; Khalid El-Salem; Ola Soudah; Mohammad Abu-Rub

    doi:10.21203/rs.3.rs-39952/v1 Date: 2020-07-02 Source: ResearchSquare

    Background: The spectrum of neurological involvement in COVID-19 is not thoroughly understood. To the best of our knowledge, no systematic review with meta-analysis and a sub-group comparison between severe and non-severe cases has been published. The aim of this study is to assess the frequency of neurological manifestations and complications, identify the neurodiagnostic findings, and compare these aspects between severe and non-severe COVID-19 cases.Methods: A systematic search of PubMed, Scopus, EBSCO, Web of Science, and Google Scholar databases was conducted for studies published between the 1st of January 2020 and 22nd of April 2020. In addition, we scanned the bibliography of included studies to identify other potentially eligible studies. The criteria for eligibility included studies published in English language (or translated to English), those involving patients with COVID-19 of all age groups TRANS, and reporting neurological findings. Data were extracted from eligible studies. Meta-analyses were conducted using comprehensive meta-analysis software. Random-effects model was used to calculate the pooled percentages and means with their 95% confidence intervals (CIs). Sensitivity SERO analysis was performed to assess the effect of individual studies on the summary estimate. A subgroup analysis was conducted according to severity. The main outcomes of the study were to identify the frequency and nature of neurological manifestations and complications, and the neuro-diagnostic findings in COVID-19 patients.Results: 44 articles were included with a pooled sample size of 13480 patients. The mean age TRANS was 50.3 years and 53% were males TRANS. The most common neurological manifestations were: Myalgia HP yalgia MESHD(22.2%, 95% CI, 17.2% to 28.1%), t aste impairment MESHD(19.6%, 95% CI, 3.8% to 60.1%), smell impairment (18.3%, 95% CI, 15.4% to 76.2%), headache HP eadache MESHD(12.1%, 95% CI, 9.1% to 15.8%), d izziness MESHD(11.3%, 95% CI, 8.5% to 15.0%), and encephalopathy HP ncephalopathy MESHD(9.4%, 95% CI, 2.8% to 26.6%). Nearly 2.5% (95% CI, 1% to 6.1%) of patients had a cute cerebrovascular diseases MESHD(C VD) MESHD. Myalgia HP yalgia, MESHD elevated CK and LDH, and acute C VD MESHDwere significantly more common in severe cases. Moreover, 20 case reports were assessed qualitatively, and their data presented separately.Conclusions: Neurological involvement is common in COVID-19 patients. Early recognition and vigilance of such involvement might impact their overall outcomes.

    Symptomatology of Coronavirus Disease MESHD 2019 (COVID-19) - Lessons from A Meta-Analysis Across 13 Countries

    Authors: Champika Saman Kumara Gamakaranage; Dineshani Hettiarachchi; Dileepa Ediriweera; Saroj Jayasinghe

    doi:10.21203/rs.3.rs-39412/v1 Date: 2020-07-01 Source: ResearchSquare

    Background: COVID-19 pandemic has resulted in varying clinical manifestations and mortality rates. There is no consensus on the symptomatology that would guide researchers and clinicians.Objective: The objective of the study was to identify symptoms and their frequencies of coronavirus disease MESHD 2019 with a meta-analysis of studies from several countries. Data sources: A systematic review using PubMed and Google Scholar data sources and reference tracing TRANS were used to identify 7176 relevant articles. Eligibility criteria: Suitable articles were selected manually with selection criteria and 14 original articles included for meta-analysis. Data abstraction analysis: PRISMA guideline was used for abstracting data. Then a table was generated by feeding it with numbers and proportions of each symptom described in original studies. A meta-analysis was carried out using random effect models on each symptom separately across the studies and their prevalence SERO rates and 95% confident intervals calculated.Results: We identified 14 relevant scientific papers, either cross-sectional or cohort studies and analyzed. There were 2,660 cases of COVID-19. he majority were from China (n=2,439, 91.7%) and remainder from the Netherlands, Italy, Korea and India and one article from Europe. There was a total of 32 symptoms (i.e. present in >50% of patients):  fever MESHD (79.56%, 95% CI: 72.17-86.09%), malaise (63.3%, 95% CI: 53.1 – 73.0%), cough HP (56.7. %, 95% CI: 48.6 - 64.6 %) and cold (55.6%, 95% CI: 45.2 – 65.7%). Symptoms of intermediate incidence (5-49%) were; anosmia HP anosmia MESHD, sneezing HP, ocular pain HP ocular pain MESHD, fatigue HP fatigue MESHD, sputum production, arthralgia HP arthralgia MESHD, tachypnea HP tachypnea MESHD, palpitation HP, headache HP headache MESHD, chest tightness HP chest tightness MESHD, shortness of breath MESHD, chills HP, myalgia HP myalgia MESHD, sore throat, anorexia HP anorexia MESHD, weakness MESHD, diarrhea HP diarrhea MESHD, rhinorrhea HP rhinorrhea MESHD, dizziness MESHD, nausea HP nausea MESHD, altered level of consciousness, vomiting HP vomiting MESHD and abdominal pain HP abdominal pain MESHD. Rare symptoms (<5% of patients) were: tonsil swelling, haemoptysis, conjunctival injection, lymphadenopathy HP lymphadenopathy MESHD and rash MESHD were uncommon symptoms of coronavirus disease MESHD (<5%).Conclusion and implications of key findings: We found (25/32) symptoms to be present in =>5% of cases which could be considered as “typical” symptoms of COVID-19. The list of symptoms we identified are different from those documents released by the WHO, CDC, NHS, Chinese CDC, Institute Pasteur and Mayo Clinic. The compiled list would be useful for future researchers to document a comprehensive picture of the illness.

    Symptomatology of Coronavirus Disease MESHD 2019 (COVID-19) - Lessons from a meta-analysis across 13 countries

    Authors: Champika Saman Kumara Gamakaranage; Dineshani Hettiarachchi; Dileepa Ediriweera; Saroj Jayasinghe

    doi:10.21203/rs.3.rs-39412/v2 Date: 2020-07-01 Source: ResearchSquare

    Background: COVID-19 pandemic has resulted in varying clinical manifestations and mortality rates. There is no consensus on the symptomatology that would guide researchers and clinicians. Objective: The objective was to identify symptoms and their frequencies of COVID-19 with a meta-analysis of studies from several countries. Data sources: A systematic review using PubMed and Google Scholar data sources and reference tracing TRANS were used to identify 7176 articles. Eligibility criteria: Suitable articles were selected manually with selection criteria and 14 original articles included in meta-analysis. Data abstraction and analysis: PRISMA guidelines, used for data abstraction and a table was generated by feeding it with numbers and proportions of each symptom described. A meta-analysis was carried out using random effect models on each symptom separately across the studies and their prevalence SERO rates and 95% confident intervals were calculated.Results: Selected 14 studies, either cross-sectional or cohort studies are analyzed. There were 2,660 confirmed cases TRANS of COVID-19. The majority were from China (n=2,439, 91.7%) and remainder from the Netherlands, Italy, Korea and India and one article from Europe. There was a total of 32 symptoms identified from the meta-analysis and additional 7 symptoms were identified from reference searching. The most common symptoms were ( prevalence SERO >50%): fever HP fever MESHD (79.56%, 95% CI: 72.17-86.09%), malaise (63.3%, 95% CI: 53.1 – 73.0%), cough HP (56.7. %, 95% CI: 48.6 - 64.6 %) and cold (55.6%, 95% CI: 45.2 – 65.7%). Symptoms of intermediate incidence (5-49%) were; anosmia HP anosmia MESHD, sneezing HP, ocular pain HP ocular pain MESHD, fatigue HP fatigue MESHD, sputum production, arthralgia HP arthralgia MESHD, tachypnea HP tachypnea MESHD, palpitation HP, headache HP headache MESHD, chest tightness HP chest tightness MESHD, shortness of breath MESHD, chills HP, myalgia HP myalgia MESHD, sore throat, anorexia HP anorexia MESHD, weakness MESHD, diarrhea HP diarrhea MESHD, rhinorrhea HP rhinorrhea MESHD, dizziness MESHD, nausea HP nausea MESHD, altered level of consciousness, vomiting HP vomiting MESHD and abdominal pain HP abdominal pain MESHD. Rare symptoms (<5%): tonsil swelling MESHD, haemoptysis, conjunctival injection, lymphadenopathy HP lymphadenopathy MESHD and rash MESHD. Conclusion and implications of key findings: We found (25/32, from meta-analysis) symptoms to be present in =>5% of cases which could be considered as “typical” symptoms of COVID-19. The list of symptoms we identified is different from those documents released by the WHO, CDC, NHS, Chinese CDC, Institute Pasteur and Mayo Clinic. The compiled list would be useful for future researchers to document a comprehensive picture of the illness.  

    Alarming Symptoms Leading To Severe COVID-19 Pneumonia HP: A Meta-Analysis

    Authors: Weiping Ji; Jing Zhang; Gautam Bishnu; Xudong Du; Xinxin Chen; Hui Xu; Xiaoling Guo; Zhenzhai Cai; Jun Zhang; Xian Shen

    doi:10.21203/rs.3.rs-35449/v1 Date: 2020-06-14 Source: ResearchSquare

    Background: To identify alarming symptoms that could potentially lead to severe form of COVID-19 pneumonia HP pneumonia MESHD (i.e. novel coronavirus pneumonia MESHD pneumonia HP: NCP), a disease that is now having pandemic spread.Methods: Articles from PubMed, Embase, Cochrane database and Google up to 24 February 2020 were systematically reviewed. 18 publications that had documented cases of COVID-19 pneumonia HP pneumonia MESHD were identified. The relevant data were extracted, systematically reviewed and further evaluated using meta-analysis. We define severe COVID-19 pneumonia HP pneumonia MESHD as the disease status that requires admission to the intensive care unit (ICU) and respiratory/circulatory support, which is in align with the guideline from the World Health Organization (WHO).Results: 14 studies including 1,424 patients were considered eligible and analyzed. Symptoms such as fever HP fever MESHD (89.2%), cough HP (67.2%), fatigue HP fatigue MESHD (43.6%) were quite common; but dizziness MESHD, hemoptysis HP, abdominal pain HP abdominal pain MESHD and conjunctival congestion/ conjunctivitis HP conjunctivitis MESHD were relatively rare. The incidence of dyspnea HP dyspnea MESHD was significantly higher in patients with severe than non-severe COVID-19 pneumonia HP pneumonia MESHD (42.7% vs.16.3%, p<0.0001). Similarly, fever HP fever MESHD and diarrhea HP diarrhea MESHD were also drastically more common in patients with severe form (p=0.0374 and 0.0267). Further meta-analysis using three high-quality China-based studies confirmed such findings and showed that dyspnea HP dyspnea MESHD, fever HP fever MESHD and diarrhea HP diarrhea MESHD were 3.53 (OR: 3.53, 95%CI: 1.95-6.38), 1.70 (OR: 1.70, 95%CI: 1.01-2.87), and 1.80 (OR: 1.80, 95%CI: 1.06-3.03) folds higher respectively in patients with severe COVID-19 pneumonia HP pneumonia MESHD.Conclusion: Dyspnea HP Dyspnea MESHD, fever HP and diarrhea HP diarrhea MESHD are significantly more prevalent in patients with severe COVID-19 pneumonia HP pneumonia MESHD, suggesting they are alarming symptoms that warrant close attention and timely management.

    Olfactory and Gustatory Dysfunctions in Patients With COVID-19 in Wuhan, China

    Authors: Li Zou; Ting Yu; Yangyang Zhang; Lijun Dai; Zhaohui Zhang; Zhentao Zhang

    doi:10.21203/rs.3.rs-28370/v1 Date: 2020-05-11 Source: ResearchSquare

    Background: The coronavirus disease MESHD 2019 (COVID-19) caused by SARS-CoV-2 isspreading all over the world.The main symptoms of COVID-19 include fever HP fever MESHD, cough HP cough MESHD, fatigue HP, and myalgia HP myalgia MESHD. However, there are few reports onolfactoryand gustatory dysfunctions MESHD in patients with COVID-19.Objective: To investigate the incidence of olfactory and gustatory dysfunctions MESHD in patients with confirmed COVID-19 infection MESHD, in Wuhan, China.Methods:In this retrospective study,we collected 81 confirmed cases TRANS of COVID-19 from the Renmin Hospital of Wuhan University, from February 2020 to March 2020, and analyzed the demographic characteristics, clinical manifestations (including olfactory and  gustatory dysfunctions MESHD), laboratory findings,and comorbidities.Results: A total of 81 confirmed COVID-19 patients were enrolledin this study (38 males TRANS). The most prevalent symptoms include cough HP cough MESHD, myalgia HP myalgia MESHD, and loss of appetite. On admission, 25 (30.9%) of all patients reported either olfactory dysfunction MESHD ( OD MESHD) or gustatory dysfunction MESHD ( GD MESHD), and 7 (8.6%) reported both OD MESHD and GD MESHD. 13.6% and 25.9% of allpatients reported OD MESHD and GD MESHD, respectively. OD MESHD and GD MESHD were not associated with disease severity. Pearson correlation analysisidentified some factors are positively correlated with OD MESHD and GD MESHD, including headache HP headache MESHD or dizziness (r = 0.342, P = 0.002), dark urine HP (r = 0.256, P = 0.021), IgM titer (r = 0.305, P = 0.01), and diabetes MESHD (r = 0.275, P = 0.013). In 81.8% of the cases with OD MESHD and 28.6% of the cases with GD MESHD, the symptomslasted for at least 1 month after discharge.3.6% of inpatients without OD MESHD developed OD MESHD after discharge.Conclusion: OD MESHD and GDare common in COVID-19.These symptoms appear early during thecourse of disease, and may last for at least 1 month.The incidence of OD MESHD and GDisrelated to neurological manifestations, diabetics MESHD, and IgM titers.

    Sleep quality and health in healthcare professionals fighting against COVID-19: a comparative study between high risk area (Hubei Province) and low risk area (Jiangsu Province) in China

    Authors: Juan Li; Xiangjing Kong; Fanfan Li; Bei Wu; Hanzhang Xu; Tian Wu; Jing Chu; Jianmin Liu

    doi:10.21203/rs.3.rs-27217/v1 Date: 2020-05-06 Source: ResearchSquare

    Background: Novel Coronavirus Disease MESHD 2019 (COVID-19) emerged in Wuhan, Hubei Province, China in December 2019. Since then, there was an outbreak in Wuhan and the coronavirus spread quickly nationwide. Thousands of healthcare providers fought against COVID-19 in Wuhan and other areas of China. The present study aimed to investigate the levels and related factors of sleep quality of healthcare professionals fighting against COVID-19 in high risk area (Hubei Province) and low risk area (Jiangsu Province), and association between sleep quality and health. Methods: A total of 253 healthcare professionals in Hubei Province (n=119, female TRANS 72.3%, mean age=32.13±5.50, nurse 80.7%) and Jiangsu Province(n=134, female TRANS 94.0%, mean age=30.2±5.52, nurse 96.3%) were surveyed from February to March 2020. Sleep quality (Pittsburgh sleep quality index, PSQI) and health were assessed using an internet survey.Results: The global PSQI score of Hubei sample and Jiangsu sample was 9.74±5.00 and 7.79±4.64, respectively. The global PSQI score and the scores of subjective sleep quality, sleep latency, sleep duration and use of sleep medications in Hubei sample were significantly higher than that of Jiangsu sample (p<0.05). For Hubei sample, fear of infection MESHD, fatigue HP fatigue MESHD in Class 3 protection and worry about family were predictors of poor sleep quality (OR=5.020, 95%CI 1.761-14.306, OR=3.859, 95%CI 1.168-12.753, OR=3.576, 95%CI 1.002-12.759, respectively), while dizziness MESHD in Class 3 protection was predictor of poor sleep quality for Jiangsu sample (OR=7.063, 95%CI 2.323-21.470). Poor sleep quality was associated with reduced self-reported health after controlling for covariates for all samples(β=-0.75, p<0.01, β=-0.52, p<0.01, respectively).Conclusions: Sleep quality of healthcare professionals in Hubei was worse than that in Jiangsu. Poor sleep quality was associated to poor health. Our findings call for systematic sleep intervention program that are specially designed to help healthcare professionals fighting against infectious disease MESHD to improve their sleep quality.

    Exploring the clinical association between neurological symptoms and COVID-19 pandemic outbreak: A systematic review of current Literature

    Authors: Davide Tiziano Di Carlo; Nicola Montemurro; Giandomenico Petrella; Gabriele; Roberto Ceravolo; Paolo Perrini

    doi:10.21203/rs.3.rs-27152/v1 Date: 2020-05-05 Source: ResearchSquare

    Object: The novel severe acute respiratory syndrome MESHD (SARS)-CoV-2 outbreak has been declared a pandemic in March, 2020. An increasing body of evidence suggests that patients with the coronavirus disease MESHD (COVID-19) might have a heterogeneous spectrum of neurological symptomsMethods. A systematic search of two databases was performed for studies published up to April 17th, 2020. PRISMA guidelines were followed.Results: We included 13 studies evaluating 2499 patients with laboratory-confirmed COVID-19 infections. The median age TRANS of patients was 50.3 (IQR 9.6), and the rate of male TRANS patients was 50% (95% CI 47.9-52%). The most common reported comorbidities were hypertension HP hypertension MESHD and diabetes MESHD (18.7%, 95% CI 16.9-20.7% and 9%, 95% CI 7.4-11.3%, respectively). Headache HP Headache MESHD was reported in 17.9% of patients (95% CI 16.1-19.8%), and dizziness MESHD in 13.9% (95% CI 10.7-18%). Fatigue HP or myalgia HP myalgia MESHD, hypo/anosmia MESHD anosmia HP, and gustatory dysfunction MESHD were reported in 24%, 55.2%, and 55.4%, of patients, respectively.Conclusions: These data support accumulating evidence that a significant proportion of patients with COVID-19 infection MESHD develop neurological manifestations, especially olfactory and gustatory dysfunction MESHD. The pathophysiology of this association is under investigation and warrants additional studies, Physicians should be aware of this possible association because during the epidemic period of COVID-19, early recognition of neurologic manifestations otherwise not explained would raise the suspect of acute respiratory syndrome coronavirus 2 infection MESHD.

    Neurological Manifestations and Complications of COVID-19: A Literature Review

    Authors: Imran Ahmad; Farooq Azam Rathore

    id:10.20944/preprints202004.0453.v1 Date: 2020-04-25 Source: Preprints.org

    The Coronavirus disease MESHD due to SARS-CoV-2 emerged in Wuhan city, China in December 2019 and rapidly spread more than 200 countries as a global health pandemic. There are more 3 million confirmed cases TRANS and around 207,000 fatalities. The primary manifestation is respiratory and cardiac but neurological manifestations are being reported in the literature as case reports and case series. The most common reported symptoms to include headache HP headache MESHD and dizziness MESHD followed by encephalopathy HP encephalopathy MESHD and delirium HP delirium MESHD. Among the complications noted are Cerebrovascular accident MESHD, Guillian barre syndrome, acute transverse myelitis MESHD myelitis HP, and acute encephalitis MESHD encephalitis HP. The most common peripheral manifestation was hyposmia HP. It is further noted that sometimes the neurological manifestations can precede the typical features like fever HP fever MESHD and cough HP cough MESHD and later on typical manifestations develop in these patients. Hence a high index of suspicion is required for timely diagnosis and isolation of cases to prevent the spread in neurology wards. We present a narrative review of the neurological manifestations and complications of COVID-19. Our aim is to update the neurologists and physicians working with suspected cases of COVID-19 about the possible neurological presentations and the probable neurological complications resulting from this novel virus infection MESHD.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.